Cost barrier keeps Malaysian parents from dengue vaccination despite two years on market

Two years after arriving in Malaysian pharmacies and private clinics, the dengue vaccine remains largely out of reach for middle-income families, creating a widening gap between those who can afford protection and those who cannot. The barrier is simple and stark: price. A full course of two doses costs more than RM400 at most private facilities—a sum that puts vaccination beyond the means of many parents who recognize the threat dengue poses but cannot justify the expense.

A. Nirmala, a teacher with four children, spent weeks calling around to compare prices before concluding the vaccine was simply not feasible for her family. Every clinic she contacted quoted her over RM400 for the two-dose series. She is not alone in this calculation. What troubles her most is not the existence of the vaccine itself, but the absence of an alternative pathway to access it. She hopes the government will eventually offer dengue vaccination at public health facilities, even at a modest cost, making it available to families like hers.

The logic behind her hope is straightforward: dengue is endemic to Malaysia. The virus circulates year-round, transmitted by mosquitoes that breed in the humid tropical climate. Children in urban and rural areas alike face genuine risk of infection. Yet the vaccine that could protect them remains confined to the private market, where affordability becomes the gatekeeping mechanism. For families earning modest incomes, the choice between paying RM400 for prevention or gambling that their children will not contract the disease is not really a choice at all.

Tarmizi, an executive with two children, finds himself in a similar position. He understands intellectually that subsidizing vaccines is expensive for government budgets, and he does not expect the state to absorb the full cost. But he also knows that at current prices, vaccination is simply not within his reach. He would pursue it if options emerged that were genuinely affordable—not free, necessarily, but priced in a way that working families could manage. The absence of such options means his children remain unvaccinated, despite his willingness to protect them if the barrier were lower.

Not everyone faces the same constraint. Sharul Nazrin, a content creator in his early thirties, has already decided to vaccinate his two children against dengue. His reasoning is economic in a different sense: he calculates that the cost of the vaccine is far less than the cost of treating dengue infection, let alone the expense and trauma of hospitalization. For him, the math is clear. He has the financial capacity to absorb the RM400 cost, and he views it as insurance against a disease that could disrupt his family's life far more severely. His decision reflects not just his ability to pay, but his assessment that the vaccine represents genuine value.

What emerges from these conversations is not disagreement about the vaccine's worth, but rather a sharp division based on household income. Parents across the economic spectrum recognize that dengue is a real threat in Malaysia and that vaccination offers meaningful protection. The vaccine itself has proven safe and effective over its two years on the market. Yet access to it has become stratified. Those with disposable income can protect their children. Those without must hope that infection does not find them, or that government policy shifts to make vaccination available through public channels at prices families can actually afford. For now, the dengue vaccine remains a private good in a country where dengue itself is a public health problem.